In the rapidly evolving landscape of healthcare, genetic testing is emerging as a pivotal force, promising to transform patient care through precision medicine. The insights derived from our genetic codes hold the potential to not only prevent diseases but also optimize treatments and promote healthier living. Yet, as highlighted in a recent MedCity News article, the journey towards realizing this potential is fraught with challenges, particularly around patient privacy and data sharing.
The Role of Information Technology
A critical component in addressing these challenges is information technology security. Organizations are turning to certifications like HITRUST to establish standards for safeguarding sensitive information. By aligning with these standards, they can protect data while facilitating the sharing necessary to enhance medical knowledge and patient care.
Collaborative Efforts and Data Sharing
Collaboration is at the heart of advancing genetic testing. Companies are contributing de-identified variant data to public health databases such as ClinVAR and the SEER Cancer Registries. These efforts, supported by cancer research registries, deepen insights and expedite advancements in patient care.
The analysis of expansive data sets is crucial for understanding diseases, allowing researchers to access, assess, and test hypotheses. This collaborative approach is paving the way for tailored treatment plans and new biological discoveries, enhancing early disease detection and intervention.
Integration with Electronic Health Records
Integrating genetic testing with Electronic Health Records (EHR) is another key strategy for improving patient outcomes. Collaborations with EHR vendors like Epic, Flatiron, and Athena streamline processes, making it easier for providers to order genetic products, optimize screening protocols, and identify potential pharmacogenetic interactions. Such collaborations break down silos, enhancing data exchange for more effective research and patient care.
Challenges and Future Trends
Despite the promising progress, the integration of genetic testing into mainstream medicine presents challenges, including managing the vast volume of genomic data. Companies are focusing on presenting complex clinical interpretations, integrating common data ontologies, overcoming data fragmentation, and ensuring data privacy to address these hurdles.
Looking ahead, the industry anticipates significant advancements, with trends like developing tests for early cancer recurrence detection and embracing a multi-omics approach that integrates RNA, proteins, and AI insights. The integration of generative AI for documentation and genetic counseling is another notable development on the horizon.
A New Era in Healthcare
Genetic testing represents more than just a scientific advancement; it signifies a fundamental shift in how we approach health and wellness. As public understanding grows and technology advances, we find ourselves at the dawn of a new era in healthcare, where our genetic code becomes a roadmap to better health and longevity.
About the Author
Kevin Haas, Ph.D., serves as the Chief Technology Officer at Myriad Genetics, where he leads the development of the precision medicine platform. With expertise in molecular simulation and machine learning, Haas is advancing genomics and digital patient/provider experiences. He has co-authored 16 peer-reviewed publications and nine patent applications, bringing a wealth of experience to his role.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Palm Beach protests erupted as intensified immigration enforcement reached the heart of Trump’s hometown, while millions in Florida brace for rising health care costs as key subsidies near expiration. At the same time, state regulators boldly declare the long‑running property insurance crisis “over,” leaving homeowners and industry professionals questioning whether true stability has finally returned.
As 2025 comes to a close, the real estate industry is shifting from uncertainty to strategic expansion. According to DWS’s Year-End 2025 Outlook, property values are stabilizing after years of repricing, capital is concentrating on high-quality assets, and Sunbelt markets—especially Florida—continue to outperform. With technology enhancing rather than replacing professional expertise, 2026 is shaping up to reward professionals who stay informed, skilled, and strategically positioned for the next cycle.
Texas capital is pouring into San Francisco’s long‑struggling commercial real estate market, with Lone Star investors buying up discounted Union Square buildings and signaling what many experts believe is the city’s market bottom. As office activity and confidence begin to return, buyers from across the country are joining the rush, turning SF’s post‑pandemic slump into one of the nation’s hottest bargain opportunities.
With 2026 HousingWire Tech100 nominations closing on December 19, the housing tech sector is accelerating at full speed. AI‑powered data platforms, digital closing breakthroughs, embedded insurance growth, and next‑generation servicing automation are reshaping real estate, mortgage, insurance, and finance. From ATTOM’s AI‑ready property intelligence to Hapi Homes’ Martha Stewart design revival, Obie’s nationwide expansion, Outamation’s servicing automation, and ServiceLink’s next‑level borrower scheduling, this year’s standout innovators are defining the future of the housing economy.
Space Investment Partners has acquired the 123,402‑square‑foot Topanga Gateway retail center in Woodland Hills for $64 million, marking another significant move in the firm’s expanding grocery‑anchored investment strategy. Located at a high‑visibility intersection and 97% occupied at the time of sale, the property strengthens the company’s push toward $500 million to $1 billion in retail acquisitions for 2026, underscoring continued investor confidence in necessity‑based retail assets.
After the Federal Reserve’s final 2025 rate cut on December 10, mortgage markets are recalibrating, giving buyers and homeowners a glimmer of relief. Rates remain lower than earlier in the year, with 30-year fixed loans at 6.12% and refinances dipping as well. This shift may spark renewed activity for buyers, refinancers, and real estate professionals heading into 2026.
